Status:
COMPLETED
Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)
Lead Sponsor:
Forest Laboratories
Conditions:
Arrhythmias
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.
Eligibility Criteria
Inclusion
- patients who completed at least 12 months on study 2000098 before inclusion in this study
Exclusion
- breast feeding or plan to become pregnant
- used ticlopidine
- were taking Class I or other Class III drugs
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
330 Patients enrolled
Trial Details
Trial ID
NCT00751738
Start Date
October 1 2002
End Date
October 1 2005
Last Update
February 1 2017
Active Locations (86)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Facility
Mobile, Alabama, United States, 36608
2
Research Facility
Little Rock, Arkansas, United States, 72205
3
Research Facility
La Jolla, California, United States, 92037
4
Research Facility
Loma Linda, California, United States, 932354